AMAG Pharmaceuticals, Inc.Find Ratings Reports
AMAG PHARMACEUTICALS INC's gross profit margin for the second quarter of its fiscal year 2020 is essentially unchanged when compared to the same period a year ago. Even though sales decreased, the net income has increased. AMAG PHARMACEUTICALS INC has average liquidity. Currently, the Quick Ratio is 1.32 which shows that technically this company has the ability to cover short-term cash needs. The company's liquidity has decreased from the same period last year.
At the same time, stockholders' equity ("net worth") has significantly decreased by 50.08% from the same quarter last year. Together, the key liquidity measurements indicate that it is relatively unlikely that the company will face financial difficulties in the near future.
STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.TheStreetRatings.com.
|Income Statement||Q2 FY20||Q2 FY19|
|Net Sales ($mil)||52.76||84.27|
|Net Income ($mil)||-13.24||-121.17|
|Balance Sheet||Q2 FY20||Q2 FY19|
|Cash & Equiv. ($mil)||147.12||261.04|
|Total Assets ($mil)||715.55||1024.2|
|Total Debt ($mil)||307.89||276.7|
|Profitability||Q2 FY20||Q2 FY19|
|Gross Profit Margin||82.53||81.59|
|Return on Assets||-36.34||-23.02|
|Return on Equity||-104.3||-66.03|
|Debt||Q2 FY20||Q2 FY19|
|Share Data||Q2 FY20||Q2 FY19|
|Shares outstanding (mil)||34.46||33.9|
|Div / share||0.0||0.0|
|Book value / share||7.23||14.73|
|Institutional Own %||n/a||n/a|
|Avg Daily Volume||1652379.0||524583.0|
SELL. The current P/E ratio is negative, which has no meaningful value in the assessment of premium or discount valuation, it simply displays that the company has negative earnings. For additional comparison, its price-to-book ratio of 1.90 indicates a significant discount versus the S&P 500 average of 3.82 and a significant discount versus the subsector average of 8.17. The price-to-sales ratio is well below both the S&P 500 average and the subsector average, indicating a discount. After reviewing these and other key valuation criteria, AMAG PHARMACEUTICALS INC proves to trade at a discount to investment alternatives.
|AMAG NM||Peers 29.54||AMAG NM||Peers 21.07|
Neutral. The absence of a valid P/E ratio happens when a stock can not be valued on the basis of a negative stream of earnings.
AMAG's P/E is negative making this valuation measure meaningless.
Neutral. The P/CF ratio, a stock’s price divided by the company's cash flow from operations, is useful for comparing companies with different capital requirements or financing structures.
AMAG's P/CF is negative making the measure meaningless.
|AMAG 32.69||Peers 18.32||AMAG NA||Peers 2.27|
Neutral. The absence of a valid price-to-projected earnings ratio happens when a stock can not be valued on the basis of a negative expected future earnings.
AMAG's ratio is negative making this valuation measure meaningless.
Neutral. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples.
Ratio not available.
|AMAG 1.90||Peers 8.17||AMAG 20.46||Peers 17.61|
Discount. A lower price-to-book ratio makes a stock more attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet.
AMAG is trading at a significant discount to its peers.
Higher. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios.
AMAG is expected to have an earnings growth rate that exceeds its peers.
|AMAG 1.70||Peers 9.06||AMAG -26.15||Peers 8.70|
Discount. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales.
AMAG is trading at a significant discount to its subsector on this measurement.
Lower. A sales growth rate that trails the subsector implies that a company is losing market share.
AMAG significantly trails its peers on the basis of sales growth.